Cerevel Corp (CERE): Growth-Adjusted Payback Ratio
Cerevel Therapeutics (CERE) strictly adheres to environmental regulations by minimizing laboratory emissions and water consumption. This daily chart from the GURU.Markets platform illustrates the P/E growth potential metric, where the 0.00 level serves as a critical benchmark. Fundamentals are supported by the development of epilepsy and Alzheimer's therapies, while a strategic acquisition by a pharma behemoth has definitively cemented the brand's status as a validated leader in neuromedicine.
Metric breakdowns and analytics for Cerevel Therapeutics (CERE)
- current quotes and average value forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
- earnings and multiples data:
CERE - Net Profit|Expected Net Profit Cerevel Therapeutics|CERE - Price to Earnings Ratio|Future Price to Earnings Multiple Cerevel Corp|CERE - PEG Multiple|EV/EBITDA Multiple Cerevel|CERE - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Cerevel Therapeutics|CERE - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cerevel.com|CERE - Net earnings per share growth this year|Earnings growth forecast for next year Cerevel Therapeutics
- sales revenue and business income indicators:
Summary company analytics:Cerevel Therapeutics Inc, CERE
To build a high-quality portfolio, it is essential to evaluate business value through the P/E ratio relative to earnings growth rates, which determines whether the price is fair given the growth dynamics. For Cerevel Therapeutics (CERE), which develops breakthrough Parkinson's disease treatments, the PEG ratio serves as a tool to align market expectations with the actual scaling potential of their innovative therapies.
Who Cerevel Therapeutics competes with
BIIB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Growth-Adjusted Payback Ratio RGC|Axsome Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate acadia-pharm.com|XENE (Xenon) - Price/Earnings to Growth Multiple|VKTX (Viking Therapeutics Inc) - Price/Earnings to Growth Ratio|SUPN (Supernus Pharma) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Catalyst Corp CPRX|Price/Earnings to Growth Ratio Denali Therapeutics (DNLI)|Price/Earnings to Growth Ratio HRMY (harmonybiosciences.com)|Biohaven - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AMLX|TRVI: Price/Earnings to Growth Multiple|Praxis Corp - Company Value to Earnings Growth Ratio|AVXL: PEG Multiple|ceribell.com - Growth-Adjusted Payback Ratio|PRTA (Prothena Corporation plc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Alector Therapeutics ALEC|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|OMER (omeros.com) - Growth-Adjusted Payback Ratio|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tevogen Bio Inc. (TVGN)|Price/Earnings to Growth Multiple ACOG|PEG Multiple cogrx.com|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|Company Value to Earnings Growth Ratio SAVA|PEG Multiple ASRT (Assertio)|Growth-Adjusted Market Cap to Net Income Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - PEG Multiple|Ovid Therapeutics Inc. (OVID) - Price/Earnings to Growth Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Ratio|CRVO - Growth-Adjusted Market Cap to Net Income|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|Price/Earnings to Growth Multiple Clene Nanomedicine (CLNN)|PEG Multiple PEPG|JUNS - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|Growth-Adjusted Payback Ratio ANVS|Grace Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Firefly Neuro|anewmeds.com (KLTO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio NRSN|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate MetaVia, Inc. MTVA|Price/Earnings to Growth Multiple NRXS (NeurAxis, Inc)|PEG Multiple heliusmedical.com (HSDT)|Price/Earnings to Growth Ratio Passage Bio PASG|Growth-Adjusted Payback Ratio NEUP|NERV - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Athira Pharma Inc|ADXN: PEG Multiple|Price/Earnings to Growth Multiple Alzamend Neuro|CYCN (Cyclerion Therapeutics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Protagenic PTIX|Price/Earnings to Growth Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Growth-Adjusted Payback Ratio|PEG Multiple ATXI (Avenue Therapeutics, Inc)|BrainStorm Cell Therapeutics Inc. (BCLI) - Price to Earnings Adjusted for Growth Rate|CARA: Price/Earnings to Growth Multiple|CHRO: Price/Earnings to Growth Ratio|ELYM: PEG Multiple|Price to Earnings Adjusted for Growth Rate Intra-Cellular Therapies, Inc. (ITCI)|Price/Earnings to Growth Ratio Longboard Pharma|Price/Earnings to Growth Ratio MRNS|Price/Earnings to Growth Multiple NKGN (NKGen Biotech, Inc.)|NRBO (neurobopharma.com) - Growth-Adjusted Payback Ratio|Sage Therapeutics - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SNPX (Synaptogenix Inc.)|Trevena, Inc - PEG Multiple|Growth-Adjusted Payback Ratio VIGL (Vigil Neuroscience)|WENA: PEG Multiple
